Banks AT, Zimmerman HJ, Ishak KG, Harter JG.
Hepatology 1995 Sep;22(3):820-7.

This study reviewed 180 reports of possible liver toxicity related to diclofenac use and submitted to the Food and Drug Administration from November 1988 through June 1991. Eighty percent of reactions occurred in women, and 70% in individuals older than 60 years. Most cases occurred during the first 8 months of treatment, but some occurred after more than a year of use, which could reflect the difficulty of establishing a link between drug use and occurrence of an adverse event after long-term treatment. Liver toxicity was detected by clinical symptoms in 67% of cases, and by laboratory analysis in the remainder. Seven of the 90 patients who presented with icterus (yellowing of the skin and the sclera of the eyes, a frequent sign of liver damage) died.

Pancreatitis associated with diclofenac.

Khan IH, Edward N.
Postgrad Med J 1993 Jun;69(812):486-7.

This article reports on the case of a 34-year old woman who developed acute pancreatitis after initiation of diclofenac therapy for painful arthropathy.

'Diaphragmlike' stricture and ulcer of the colon during diclofenac treatment.

Whitcomb DC, Martin SP, Trellis DR, Evans BA, Becich MJ.
Arch Intern Med 1992 Nov;152(11):2341-3.

This article reports on the case of a woman who developed an intestinal ulcer causing blood loss and anemia and a colonic stricture (the narrowing of the colon due to presence of scar tissue), while on diclofenac therapy. Discontinuation of treatment resulted in resolution of anemia and blood loss, indicating a casual role of diclofenac in this complication.

Nonsteroidal anti-inflammatory drug-induced colonic strictures: two cases and literature review.

Gargot D, Chaussade S, d'Alteroche L, Desbazeille F, Grandjouan S, Louvel A, et al.
Am J Gastroenterol 1995 Nov;90(11):2035-8.

This article describes two patients who developed colonic strictures while taking the nonsteroidal anti-inflammatory drugs diclofenac and phenylbutazone. One patient had to undergo removal of the right part of the colon.

Severe hepatotoxicity associated with bromfenac sodium.

Moses PL, Schroeder B, Alkhatib O, Ferrentino N, Suppan T, Lidofsky SD.
Am J Gastroenterol 1999 May;94(5):1393-6.

This article reports on the case of a case of 40-year-old woman who developed subacute hepatitis and liver failure after one month of treatment with the nonsteroidal anti-inflammatory drug bromfenac. Liver failure was accompanied by encephalopathy, fluid retention and spontaneous bacterial peritonitis.

Fatal submassive necrosis of the liver associated with piroxicam.

Planas R, De Leon R, Quer JC, Barranco C, Bruguera M, Gassull MA.
Am J Gastroenterol 1990 Apr;85(4):468-70.

This article reports on the case of a 64 year-old woman who developed acute hepatitis followed by liver failure and death after 3 weeks of piroxicam (Feldene) use.

Hepatitis, toxic epidermal necrolysis and pancreatitis in association with sulindac therapy.

Klein SM, Khan MA.
J Rheumatol 1983 Jun;10(3):512-3.

This article reports on the case of two patients who developed severe adverse reactions to Sulindac therapy. One patient developed acute toxic hepatitis and Stevens-Johnson's syndrome followed by death. The other patient developed acute pancreatitis in two instances following ingestion of the drug.

Sulindac-associated hepatic injury: analysis of 91 cases reported to the Food and Drug Administration.

Tarazi EM, Harter JG, Zimmerman HJ, Ishak KG, Eaton RA.
Gastroenterology 1993 Feb;104(2):569-74.

This study evaluated 338 reports of sulindac-associated liver injury submitted to the Food and Drug Administration, and found that 247 of them were unconvincingly related to the drug. Of the remaining 91 cases, 4 were deaths, 3 from severe hypersensitivity and one from fulminant liver failure.

The problems and pitfalls of NSAID therapy in the elderly (Part II).

Johnson AG; Day RO.
Drugs Aging, 1(3):212-27 1991 May.

This article discusses the increased risk of nonsteroidal anti-inflammatory drugs (NSAID) toxicity, especially pronounced in the elderly, derived by the interaction between NSAIDS and drugs such as: other NSAIDs, aminoglycosides, lithium and various antihypertensive, anticoagulant, anticonvulsants and hypoglycaemic drugs.